Biocept's patented Target Selector™ technology enables new specimen type--cerebrospinal fluid (CSF)--to identify biomarkers that can aid physicians in making treatment decisions SAN DIEGO , Jan. 14, 2020 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy
Biocept further expands its patent estate for capturing and detecting target cells of interest, including circulating tumor cells SAN DIEGO , Jan. 8, 2020 /PRNewswire/ -- Biocept, Inc . (Nasdaq: BIOC), a leading commercial provider of molecular offerings designed to provide physicians with
SAN DIEGO , Dec. 12, 2019 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC) (" Biocept " or the "Company"), a leading commercial provider of liquid biopsy solutions, today announced that on December 11, 2019 it closed its previously announced underwritten public offering of 24,600,000 shares of its
SAN DIEGO , Dec. 9, 2019 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC) (" Biocept " or the "Company"), a leading commercial provider of liquid biopsy solutions, today announced the pricing of an underwritten public offering of 24,600,000 shares of its common stock (or pre-funded warrants to
Target Selector™ platform demonstrates ability to accurately detect, enumerate, and interrogate circulating tumor cells (CTCs) in a cohort of over 1,500 patients, representing various clinical and treatment stages of breast cancer SAN DIEGO , Dec. 3, 2019 /PRNewswire/ -- Biocept, Inc .
Biocept's patented Target Selector™ test for identification of TRK proteins enables physicians to rapidly and cost-effectively identify the potential presence of NTRK fusions used to inform on treatment options SAN DIEGO , Nov. 21, 2019 /PRNewswire/ -- Biocept, Inc.
- Revenues reached a record $1.5 million, up 101% over the third quarter of 2018 and up 28% over the second quarter of 2019 - The number of commercial samples received increased 66% over the third quarter of 2018 and 12% over the second quarter of 2019 - Cost of revenue reduced 23% on a per
Patented Blood Collection Tube and Sample Collection Shipping Kit enable the safe transport at room temperature of patient specimens containing both circulating tumor DNA or RNA (ctDNA or ctRNA) and circulating tumor cells (CTCs) SAN DIEGO , Nov. 7, 2019 /PRNewswire/ -- Biocept, Inc.
SAN DIEGO , Nov. 6, 2019 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that it will release financial
Data highlight strong analytical and clinical performance of Biocept's proprietary technologies, including circulating tumor DNA (ctDNA) assays, circulating tumor cell (CTC) capture, and molecular testing kits SAN DIEGO , Nov. 4, 2019 /PRNewswire/ -- Biocept, Inc .
